E-602
Showing 1 - 25 of 5,480
Oncology, Melanoma, Ovarian Cancer Trial in United States (E-602, Pembrolizumab)
Recruiting
- Oncology
- +16 more
- E-602
- Pembrolizumab
-
Grand Rapids, Michigan
- +4 more
May 27, 2022
Achondroplasia Trial in Worldwide (Recifercept)
Active, not recruiting
- Achondroplasia
- Recifercept
-
Irvine, California
- +13 more
Jan 20, 2023
Achondroplasia Trial in Worldwide (Recifercept)
Recruiting
- Achondroplasia
- Recifercept
-
Aliso Viejo, California
- +13 more
Aug 3, 2022
Coronary Artery Disease Trial in Korea, Republic of (Prasugrel 5mg, Ticagrelor 60mg)
Unknown status
- Coronary Artery Disease
- Prasugrel 5mg
- Ticagrelor 60mg
-
Changwon, Gyeongsangnam-do, Korea, Republic of
- +7 more
Jan 28, 2021
Transfusional Iron Overload, Beta-Thalassemia Trial in Worldwide (SPD602)
Terminated
- Transfusional Iron Overload
- Beta-Thalassemia
-
Boston, Massachusetts
- +8 more
Jun 10, 2021
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck Trial in Worldwide (E7050, Cetuximab)
Completed
- Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
-
Tucson, Arizona
- +22 more
Dec 3, 2021
Iron Overload Due to Repeated Red Blood Cell Transfusions Trial in Worldwide (SPD602)
Terminated
- Iron Overload Due to Repeated Red Blood Cell Transfusions
-
Los Angeles, California
- +11 more
Jun 11, 2021
Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome Trial in Worldwide (Guadecitabine)
Terminated
- Acute Myeloid Leukemia
- Myeloid Dysplastic Syndrome
-
Buffalo, New York
- +20 more
Jan 21, 2022
Leukemia, Myeloid, Acute, MDS Trial in Worldwide (CC-90009)
Recruiting
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes
-
New Haven, Connecticut
- +23 more
Aug 1, 2022
Transfusional Iron Overload, Beta-thalassemia Trial in Worldwide (SPD602 (FBS0701, SSP-004184))
Completed
- Transfusional Iron Overload
- Beta-thalassemia
- SPD602 (FBS0701, SSP-004184)
-
Oakland, California
- +8 more
May 30, 2021
Clinical & Anthropometric Characteristics of Achondroplasia.
Active, not recruiting
- Achondroplasia
-
Torrance, California
- +32 more
Nov 16, 2022
Relapsing-Remitting Multiple Sclerosis Trial in Worldwide (Ocrelizumab, Ocrelizumab Placebo, Fingolimod)
Recruiting
- Relapsing-Remitting Multiple Sclerosis
- Ocrelizumab
- +3 more
-
La Jolla, California
- +66 more
Jan 27, 2023
Eczema, Atopic Dermatitis Trial in Worldwide (KY1005, Placebo)
Active, not recruiting
- Eczema
- Atopic Dermatitis
- KY1005
- Placebo
-
Fremont, California
- +102 more
Dec 13, 2022
Hidradenitis Suppurativa (HS) Trial in Worldwide (Upadacitinib, Placebo Upadacitinib)
Completed
- Hidradenitis Suppurativa (HS)
- Upadacitinib
- Placebo Upadacitinib
-
Phoenix, Arizona
- +25 more
Mar 22, 2022
The BCI 602 BONEBRIDGE Post-Market Clinical Follow-up Study
Recruiting
- Hearing Loss
- +5 more
- Bone Conduction Implant
-
Innsbruck, Austria
- +7 more
Jan 21, 2022
Hidradenitis Suppurativa Trial in Worldwide (Lutikizumab, Placebo)
Recruiting
- Hidradenitis Suppurativa
- Lutikizumab
- Placebo
-
Phoenix, Arizona
- +54 more
Jan 26, 2023
HBV, Chronic HBV Infection Trial in Worldwide (TAF, TDF, TAF Placebo)
Active, not recruiting
- HBV
- Chronic HBV Infection
- TAF
- +3 more
-
Los Angeles, California
- +159 more
Mar 17, 2022
Multiple Myeloma Trial in Worldwide (Elranatamab, Lenalidomide)
Recruiting
- Multiple Myeloma
-
Benowa, Queensland, Australia
- +132 more
Jan 24, 2023
Endometriosis Trial in Worldwide (75 mg linzagolix tablet, 200 mg linzagolix tablet, Placebo tablet to match 75 mg linzagolix
Active, not recruiting
- Endometriosis
- 75 mg linzagolix tablet
- +5 more
-
Dothan, Alabama
- +46 more
Jan 12, 2023